Millions in Pain. One Mission to Heal.

Osteoarthritis is one of the most common and debilitating chronic conditions in adults, yet treatment innovation continues to fall short.

Over 32 million people in the U.S. live with OA, enduring chronic pain, stiffness, and declining mobility. For many, the burden extends beyond the physical—leading to depression, loss of independence, and reduced quality of life.

Current therapies focus on masking symptoms. None are designed to restore joint function or halt disease progression.

People deserve better.

SEV-101

A Regenerative, Disease-Modifying Exosome Therapeutic for Osteoarthritis

SEV-101 is a first-in-class, off-the-shelf intra-articular injection designed to regenerate cartilage and modify the progression of osteoarthritis (OA). In validated preclinical models, SEV-101 has demonstrated statistically significant cartilage regeneration, offering a transformative alternative to symptom-masking treatments.

A New Era in OA Treatment

  • Disease-modifying potential: Targets the root pathophysiology of OA rather than just alleviating pain.

  • Reverses progression: Promotes long-lasting cartilage regeneration.

  • May eliminate the need for joint replacement surgery, changing the treatment paradigm for millions.

Engineered for Precision and Scalability

Derived from iPSC-based cartilage, SEV-101 delivers a scalable and reproducible source of potent exosomes rich in regenerative bioactive molecules.

Multi-Modal Mechanism of Action

SEV-101 activates key pathways involved in:

  • Joint tissue repair

  • Inflammation resolution

  • Cartilage health and regeneration

With its multi-modal MOA, SEV-101 addresses both the symptoms and the underlying drivers of OA, positioning it as the first regenerative, disease-modifying OA therapeutic.

SEV-101 contents are known to promote key pathways in Cartilage Regeneration, Extracellular Matrix Production, Reduced Inflammation, and Chondrogenic Differentiation suggesting a multi-modal MOA.